Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: PuuliTuku
Search This Board: 
Last Post: 10/18/2017 3:24:06 PM - Followers: 190 - Board type: Free - Posts Today: 0

Apricus Biosciences, Inc. (APRI)





Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:



NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.

The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.


Share Structure:
Outstanding Shares

Authorized Shares

Investor Relations:
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933




All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


Image result for vitaros                                                  

Image result for vitaros

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI News: Securities Registration Statement (simplified Form) (s-3/a) 10/11/2017 05:06:05 PM
APRI News: Apricus Biosciences to Present at the 2017 BIO Investor Forum 10/10/2017 07:00:30 AM
APRI News: Apricus Biosciences to Present at the 2017 BIO Investor Forum 10/10/2017 07:00:00 AM
APRI News: Small Company Offering and Sale of Securities Without Registration (d) 09/27/2017 01:05:43 PM
APRI News: Securities Registration Statement (simplified Form) (s-3) 09/25/2017 04:52:52 PM
#27403 mecosmo2 10/18/17 03:24:06 PM
#27402   Apricus Biosciences to Present at the 2017 BIO mecosmo2 10/10/17 07:44:00 AM
#27401   3 million shares coming onto the market at IPO$ 10/03/17 11:52:55 AM
#27400   Title of Class of Securities to be Registered IPO$ 10/03/17 11:52:05 AM
#27399   New Update: Apricus Biosciences, Inc. (NASDAQ CM: APRI) IPO$ 10/03/17 11:50:43 AM
#27398   Pascoe has no intentions of selling. He can casinokid11211 10/01/17 09:05:32 AM
#27396   3 ways to become a Profitable Stock Trader Ronnieg 09/22/17 07:18:03 PM
#27394   ARMISTICE CAPITAL LLC now owns 9.6% of APRI PuuliTuku 09/22/17 06:43:19 AM
#27393   there are many pharmacies right over the border eicoman 09/21/17 03:00:39 PM
#27392   Yes the product is available in Mexico, I mecosmo2 09/21/17 12:15:58 PM
#27391   supposed to be, check with the pharmacies down eicoman 09/20/17 10:21:28 AM
#27390   Hey Eicoman -- is the Mexico launch still Bryce Harper 09/19/17 04:14:07 PM
#27389   There you have it. Did they need the OldtimeramI 09/12/17 11:23:30 AM
#27388   Pascoe wore yours out before he could get casinokid11211 09/12/17 06:08:24 AM
#27387   Good one Casino !!!! You forgot to include Aprilov 09/11/17 06:05:34 PM
#27386   Pascoe's dic got to be ready to fall casinokid11211 09/11/17 05:41:04 PM
#27385   I say Vitaros does get approved. Buyout price casinokid11211 09/10/17 08:42:02 AM
#27383   Apricus Biosciences to Present at the Rodman & mecosmo2 09/05/17 07:11:58 AM
#27382   apricus,.SA . Shares have lost over 90% of mecosmo2 09/04/17 09:25:40 AM
#27379   Could be but there's cheaper toilet paper. PuuliTuku 09/02/17 07:15:57 PM
#27378   Denner ran out of toilet paper and he casinokid11211 09/02/17 09:55:34 AM
#27377   Sec filing today, looks like A.Denner bought 6104 PuuliTuku 09/01/17 05:10:20 PM
#27376   I thought it use to be 6 months OldtimeramI 08/31/17 12:36:14 PM
#27375   Apricus in-licensed the U.S. development and commercialization rights mecosmo2 08/31/17 08:18:05 AM
#27374   Go APRI....let us dream! TheKobra 08/31/17 08:08:34 AM
#27373   Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class Aprilov 08/31/17 07:40:10 AM
#27372   I am going only on memory, but I Bryce Harper 08/31/17 03:37:42 AM
#27371   Why would they have to do a capital OldtimeramI 08/31/17 02:08:23 AM
#27370   Why would they have to do a capital mean gene 08/30/17 03:58:30 PM
#27369   nice find Apri., I agree eicoman 08/30/17 01:28:46 PM
#27368   -End of October for possible FDA acceptance of OldtimeramI 08/30/17 12:51:23 PM
#27367   Anything is possible. OldtimeramI 08/30/17 12:28:36 PM
#27366   Apricus approval could lead to Allergan takeover, says Aprilov 08/30/17 08:06:04 AM
#27365   My shareprice guesstimate after filing was in 2.5$'sh PuuliTuku 08/29/17 08:10:23 AM
#27364   yes you called it PT ! Chillin up north 08/29/17 07:31:14 AM
#27363   Looks like I was right for once. PuuliTuku 08/29/17 07:19:22 AM
#27362   NDA filed Chillin up north 08/29/17 07:09:20 AM
#27361   Pop goes the whistle Tdash 08/24/17 01:55:50 PM
#27359   where is ED COX ?? 28 countries have jiiimmy3 08/18/17 06:03:20 PM
#27358   Good post! Concise on point good estimate for mecosmo2 08/18/17 12:45:56 PM
#27357   enough cash thru 3q 2018 ....... 12.8 jiiimmy3 08/18/17 01:22:28 AM
#27356   APRI for sale. Are you nuts. Pascoe would casinokid11211 08/12/17 10:00:24 AM
#27355   The tax loss for Apri is 300 million Aprilov 08/09/17 11:22:26 AM
#27354   It looks like the board has guesstimates Ranging mecosmo2 08/08/17 12:27:53 PM
#27353   didn't know about the lawsuit, thanks, doesn't seem eicoman 08/08/17 09:58:11 AM
#27352   The question is, Why would a huge growing OldtimeramI 08/08/17 01:59:57 AM
#27351   The question is, Why would a huge growing eicoman 08/07/17 03:22:18 PM
#27350   I like it, but should that be through? Clariske 08/07/17 11:16:30 AM
#27349   I see, thanks for correction. PuuliTuku 08/07/17 09:28:49 AM
#27348   It looks like we did wake up the mecosmo2 08/07/17 09:24:24 AM